Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 4
2019 2
2020 4
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Practical aspects of CAR-T cell therapy.
Jana M, Tomáš J, Michal K, Kateřina B, Juraj U, Ivo D, Zdeněk K, Roman H. Jana M, et al. Klin Onkol. 2022 Winter;35(1):44-54. doi: 10.48095/ccko202244. Klin Onkol. 2022. PMID: 35236081 Review. English.
Venetoclax: A new wave in hematooncology.
Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Mihalyova J, et al. Exp Hematol. 2018 May;61:10-25. doi: 10.1016/j.exphem.2018.02.002. Epub 2018 Mar 2. Exp Hematol. 2018. PMID: 29477371 Free article. Review.
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. Jelinek T, et al. Among authors: mihalyova j. Immunology. 2017 Nov;152(3):357-371. doi: 10.1111/imm.12788. Epub 2017 Aug 4. Immunology. 2017. PMID: 28685821 Free PMC article. Review.
CD38 targeted treatment for multiple myeloma.
Jelínek T, Mihályová J, Hájek R. Jelínek T, et al. Among authors: mihalyova j. Vnitr Lek. 2018 Fall;64(10):939-948. Vnitr Lek. 2018. PMID: 30590941 English.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, Vodárek P, Zuchnická J, Mihályová J, Urbanová R, Turcsányi P, Lysák D, Novák J, Brejcha M, Líkařová T, Vodička P, Baranová J, Trněný M, Doubek M; Czech CLL Study Group. Špaček M, et al. Among authors: mihalyova j. Br J Haematol. 2023 Jul;202(1):40-47. doi: 10.1111/bjh.18736. Epub 2023 Mar 27. Br J Haematol. 2023. PMID: 36971061
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R. Jelinek T, et al. Among authors: mihalyova j. Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. Am J Hematol. 2019. PMID: 30370955 Free article. No abstract available.
14 results